近日，一年一度的美国临床肿瘤年会泌尿生殖系分会（ASCO-GU）在旧金山Moscone会议中心开幕。我院泌尿外科团队应邀参会并作9篇壁报交流，是国内投稿采纳数最多的医院。

本次会议为期3天，全球超4500人注册参会, 收到摘要投稿937篇。受国内疫情影响，2019年会超过百人的中国泌尿肿瘤学者因奋战于国内抗击新冠疫情的第一线而缺席本次会议，仅数位在美学习的中国医生出席。我院泌尿外科在美学习的刘振华、赵劲歌两位医师代表科室团队参会。

中国学者共有19篇摘要被采纳参与壁报交流，其中包括我院泌尿外科团队5项前列腺癌和4项肾癌相关研究。研究涉及对前列腺癌特殊病理类型---导管内癌和肾癌罕见类型--- FH基因缺失性肾癌的基因组学研究、晚期前列腺癌和肾癌的精准治疗分子标志的选择，以及晚期肿瘤新型治疗模式的探索，研究内容受到与会专家一致好评。我院腹部肿瘤科毕锋主任团队一项关于晚期尿路上皮癌的研究也于会议展出。

此次大会充分展示了我院泌尿外科科研与临床的实力，有助于提升我院泌尿外科以及中国泌尿外科的国际影响力。

附：2020 ASCO GU华西医院泌尿外科9项研究：

#133 The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone

#192 Distinctive landscape of genetic mutation in patients with intraductal carcinoma of the prostate (IDC-P)

#196 High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients

#244 Exosomal TUBB3 mRNA expression level to predict prognosis for abiraterone treatment in metastatic prostate patients

#369 The efficacy and safety of radical prostatectomy and radiotherapy in high risk prostate cancer: A systematic review and meta-analysis

#688 The prognostic value of body fat components in metastasis renal cell carcinoma patients treated with TKIs

#693 Occurrence of tyrosine kinase inhibitors-induced renal impairment and its predictive value for the prognosis of patients with metastatic renal cell carcinoma

#694 Individualized dosing schedule of sunitinib switched through plasma concentration monitoring in patients with metastatic renal cell carcinoma

#717 Genomic landscape and immune microenvironment features of FH-deficient renal cell carcinoma